TRANSVAC2 offers technical services at all stages of the Vaccine R&D pipeline to support the development of prophylactic and therapeutic vaccines for human and veterinary use.

Stay tuned for the
next open TNA call

TRANSVAC: New Vaccines Faster

TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020.  The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.

Support to development of vaccines against COVID19

Image by CDC

“Rapid progress towards the development of potent vaccines can only happen through concerted and coordinated efforts around Europe and the world – and TRANSVAC2 is well positioned to facilitate such efforts.” - Dr. Hilde Depraetere, TRANSVAC2 Coordinator


To support of the global effort to accelerate the development of a vaccine against Sars-CoV-2, TRANSVAC2 launched in April 2020 a specific call for applications focused on the development of novel COVID-19 vaccines. 


Consequently, a variety of TRANSVAC2 services, from antigen discovery to preclinical and clinical trial support (In total 31 services), will be delivered to help eight awarded research groups from SMEs and public institutions to speed-up the COVID-19 vaccine development pipeline.

 This initiative is fully supported by the European Commission which provides, additional top-up funds worth EUR 4 millions.

Excerpt adapted from

SARS-CoV-2 illustration:Centers for Disease Control and Prevention (CDC)  Image by: CDC/ Alissa Eckert, MS; Dan Higgins, MAMS

Latest News, events & more...


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.